Allogene Therapeutics (ALLO) Non Operating Income (2018 - 2026)

Allogene Therapeutics has disclosed Non Operating Income across 9 years of filings, most recently posting $3.5 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $3.5 million, down 36.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (down 52.2% YoY), and the FY2025 annual result was $215000.0, down 98.66% from the prior year.
• Non Operating Income came in at $3.5 million for Q1 2026 at Allogene Therapeutics, up from $247000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $18.0 million in Q4 2024 to a low of -$3.7 million in Q2 2022.
• The 5-year median for Non Operating Income is $1.3 million (2023), against an average of $2.2 million.
• Across the five-year window, Non Operating Income plunged 591.9% in 2022 and soared 2793.57% in 2024, its largest moves.
• Allogene Therapeutics' Non Operating Income stood at -$3.6 million in 2022, then surged by 81.61% to -$669000.0 in 2023, then jumped by 2793.57% to $18.0 million in 2024, then slumped by 98.63% to $247000.0 in 2025, then jumped by 1310.93% to $3.5 million in 2026.
• The last three Non Operating Income figures came in at $3.5 million (Q1 2026), $247000.0 (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.